Life Sciences

Rentschler Biopharma, a global contract development and manufacturing organization with offices in Germany and Milford, has named Christian Schetter as its new chief scientific officer, effective this past Wednesday, according to a Monday announcement.

Miach Orthopaedics, a Westborough bioengineering plant specializing in surgical implants, announced Monday the first patient successfully treated using the company’s Bridge-Enhanced ACL Repair implant.

Marlborough diagnostic company Immunovia, Inc. announced on Monday it has acquired a global license from the South Korean company JW BioScience’s intellectual property portfolio, granting Immunovia global commercial rights for two biomarkers.

A 33,800-square-foot office building on Otis Street in Northborough was sold for $3.15 million to Ciminelli Real Estate Corporation in Buffalo, according to the Worcester Registry of Deeds. 

The Reactory Summit, a one-day biomanufacturing conference to be held at the Beechwood Hotel, has been postponed from Oct. 13 to April 6, according to The Reactory’s website.

Marlborough company Sunovion Pharmaceuticals announced on Thursday it granted exclusive commercial license rights in Europe to Portugese company Bial for Sunovion's KYNMOBI, an under-the-tongue drug treating OFF episodes in patients with Parkinson’s disease.

Arch Therapeutics, a Framingham biotechnology company specializing in wound care and biosurgical devices, announced Thursday a partnership with Lovell Government Services, a Floridia medical supply distributor.

Framingham biotech company SCIEX on Wednesday announced the launch of two new initiatives, a software and a capillary electrophoresis system.

Pillar Biosciences in Natick announced on Wednesday the appointment of Randy Pritchard as CEO, as the company’s founder and previous CEO Dr. Gang Song will transition to the role of chairman of the board, according to a press release.

HebeCell Corp., a Natick research company focused on therapies for cancer and autoimmune disease, announced on Tuesday it has closed a $53-million Series A financing for an off-the-shelf stem cell product.